New Chief Wants to Grow IBRI’s Global Reputation
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThe new chief executive officer of the Indiana Biosciences Research Institute in Indianapolis says he wants to see the institute emerge as a global leader of innovative science focusing on human health. Dr. Alan Palkowitz, who also serves as a senior research professor of medicine at the Indiana University School of Medicine, was named to his new role earlier this month. He says he wants the IBRI to serve as a key partner for the broader life sciences community.
In an interview with Business of Health Reporter Kylie Veleta, Palkowitz said this is a very interesting time for Indiana’s life sciences sector.
“When I look at the scientific landscape and starting, for example, here at IBRI, there has already been some tremendous work that has been initiated focused on translational medicine and trying to advance disease understanding and I look at that as just part of a larger concentration of talent and capabilities that are part of our Midwest community,” said Palkowitz.
Palkowitz says ultimately, the institute wants to contribute to growing the life sciences community by working on initiatives to create jobs, to attract and retain talent, and help Indiana and the Midwest emerge as a powerhouse in advancing human health.
The IBRI recently relocated its headquarters to the recently-opened Innovation Building 1 at the 16 Tech innovation district in Indianapolis. Palkowitz says being at the district puts the institute at a nexus point.
“We’re going to be at the intersection of a lot of key discussions, a lot of key investment, a lot of key scientific collaborations. So that is really important for us to really be at that focal point. I think that will really help propel our identity but also very importantly, really bring the community together with this common mission to advance human health and build a broader enterprise for the Midwest.”
Palkowitz says he wants to leverage his experience both in the private sector with his time at Eli Lilly and Co. (NYSE: LLY) and in academia to achieve the IBRI’s goals.